We offer the following significant opportunities for the biopharmaceutical industry:

• Broad range of expression capabilities. ProCellEx^® is able to produce a broad array of complex glycosylated proteins, some of which are difficult to produce in mammalian, bacterial and  and yeast cell-based systems.
• Significantly lower capital and production costs.
• Rapid scalable manufacturing based on requirements. Elimination of risk of mammalian viral transmission or infection.
• Biologic Optimization: ProCellEx^® has internal capabilities developed to improve the biologic dynamics of an expressed protein, and thus to develop modified therapeutic proteins with potentially superior clinical profiles.
• Opportunities to penetrate patent-protected markets.
• Potential ability to administer active therapeutic enzymes orally.
• In-house capabilities for clinical development and regulatory affairs.

From Concept to Market

	Selecting the target protein-drug candidate
	Gene of interest engineering Plant cells are genetically engineered to express the gene of interest
	Protein drug enhancement modifications Improving biological dynamics to bring forth improved clinical profiles
	Pilot production with the ProCellEx® Platform Isolation and Purification for parentally delivered and inhaled  biopharmaceuticals Isolation of intact plant cells for orally delivered products
	Product development Clinical development and regulatory activity
	Commercial production Scaling up the cell suspension to produce commercial amounts of the target protein